AOD-9604
Anti-Obesity Drug 9604 · hGH fragment 176-191 analog · Tyr-hGH(177-191) · lipolytic fragment
Last updated
At a glance
Overview
AOD-9604 occupies a specific niche in the fat-loss toolkit: it's the lipolytic tail of human growth hormone — residues 176–191 with an added N-terminal tyrosine — isolated away from the anabolic, IGF-1-raising, glucose-disrupting side of the GH molecule. What you're left with is a peptide that nudges adipocytes toward lipolysis via β3-adrenergic receptor upregulation without touching HPTA, IGF-1, insulin sensitivity, or aromatase. For the physique-focused crowd running a serious cut — and for GLP-1 users trying to bias substrate burn toward fat rather than lean tissue — that's a clean signal worth having.
"Chronic oral administration of AOD9604 induced a reduction in body weight and body fat, with no change in insulin, glucose, or IGF-I levels." — Heffernan et al., Am J Physiol Endocrinol Metab (2000)
The honest pitch: AOD-9604 is a mild adjunct, not a replacement for HGH and nowhere near a GLP-1 on the scale. Users who frame it as "HGH without the sides" walk away disappointed. Users who slot it into a real deficit — typically 300 mcg SC fasted before morning cardio, often stacked with CJC-1295/Ipamorelin or low-dose HGH — tend to report it does exactly what it says: a steady lipolytic pull on stubborn depots, zero sides, zero bloodwork drama, no PCT. It's also one of the few peptides where women can run the same protocol as men without hormonal considerations.
What This Guide Covers#
Below we break down the evidence-based dosage ranges (beginner through advanced SC protocols), reconstitution and injection mechanics, cycle length, the best stacks (GH secretagogue, GLP-1 adjunct, on-cycle metabolic cleanup), realistic fat-loss expectations, the full side effect profile from ~925 clinical subjects, and the common pitfalls — short runs, oral formulations, and treating it like a standalone drug — that make people write AOD off before it has a chance to work.
How AOD-9604 works
AOD-9604 is a 16-amino-acid synthetic analog of the C-terminal lipolytic domain of human growth hormone (residues 177–191), with an added N-terminal tyrosine for stability. It was engineered at Monash University to isolate the fat-burning arm of GH from the growth-promoting, IGF-1-elevating, and diabetogenic arms — so the entire point of the molecule is what it doesn't do as much as what it does. It does not bind the GH receptor, does not raise IGF-1, and does not impair glucose tolerance.
β3-Adrenergic Receptor Upregulation#
The central chronic mechanism is upregulation of β3-adrenergic receptor (β3-AR) expression on adipocytes. β3-AR is the dominant lipolytic receptor on fat cells — it's the receptor catecholamines (adrenaline, noradrenaline) use to tell fat to release fatty acids. In obesity, β3-AR expression is suppressed, which is part of why stubborn fat is stubborn. AOD-9604 restores it.
"AOD9604 increased beta(3)-AR mRNA in fat from obese mice and normalized levels to that seen in lean controls, highlighting an important mechanism for the selective fat-reducing effects of this hGH fragment." — Heffernan M, Summers RJ, Thorburn A, et al. Endocrinology, 2001
Practically, this means AOD sensitizes fat tissue to the lipolytic signals your own nervous system is already producing during fasted cardio, stimulants, or a cold environment. That's why the standard community protocol — AM fasted, 30–45 minutes before cardio — lines up with the mechanism: you're dosing ahead of an endogenous catecholamine pulse that the β3-AR is now better equipped to hear.
This is a chronic adaptation, not an acute effect. Receptor density changes take weeks, which is why 4-week runs underwhelm and 10–12 week runs are where users actually notice something.
Direct Lipolysis and Suppression of Lipogenesis#
Alongside the receptor-level change, AOD-9604 has direct effects on fat-cell metabolism: it increases hormone-sensitive lipase (HSL) activity (the enzyme that liberates fatty acids from triglyceride stores) and suppresses acetyl-CoA carboxylase–driven lipogenesis (the pathway that builds new fat). The net substrate flux in adipose tissue biases toward oxidation and away from storage.
"Chronic oral administration of AOD9604 induced a reduction in body weight and body fat, with no change in insulin, glucose, or IGF-I levels." — Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Am J Physiol Endocrinol Metab, 2000
β3-AR knockout mice lose the chronic weight-loss response but retain acute fat oxidation — so there's a β3-independent lipolytic signal running in parallel, with β3 upregulation doing most of the long-term work.
Dissociation From the GH Receptor#
The reason AOD-9604 exists as a separate molecule is that this C-terminal fragment retains GH's lipolytic activity without engaging the GH receptor. That dissociation is the whole pitch. It was demonstrated in the original 1978 Ng & Bornstein work that mapped GH's lipolytic signal to this specific C-terminal region:
"Fragments corresponding to 177-191 of human GH retained potent lipolytic activity without the diabetogenic or growth-promoting effects of native GH." — Ng FM, Bornstein J. Am J Physiol, 1978
For the physique-focused user, the implication is concrete: no IGF-1 elevation means no tissue-growth sides (no carpal tunnel, no water retention, no organ growth, no joint pain, no anabolic upside either), and no GHR-mediated insulin antagonism means no insulin-sensitivity hit — which is the specific reason this peptide slots cleanly into stacks that already carry an IGF-1 and insulin load (HGH, slin, orals). You get a lipolytic signal on top without stacking another metabolic stressor.
Absence of Systemic Endocrine Disruption#
Across six Phase I/II trials running ~900 subjects, AOD-9604 produced no meaningful changes in IGF-1, fasting glucose, HbA1c, insulin sensitivity, or lipid parameters at any tested dose.
"Across six phase I/II clinical trials, AOD9604 has not been shown to produce any significant changes in IGF-1, glucose, or lipid parameters in humans at any tested dose." — Jensen MD. Obesity, 2006
This is the mechanistic basis for AOD's reputation as the "clean" peptide — no HPTA involvement, no aromatization, no androgenic activity, no PCT, minimal bloodwork burden. The trade-off is equally mechanistic: because it doesn't touch those axes, it also doesn't drive any of the recovery, tissue, or anabolic effects that come with them. It does one thing, and the one thing is mild but specific — sensitize fat to catecholamines and tilt adipose substrate flux toward oxidation. Framed correctly, that's exactly what you want in a lipolytic adjunct sitting underneath a real deficit and a serious stack.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 250–300 mcg | Once daily | Documented entry-level range |
| Mid | 300–500 mcg | Once daily | Most commonly studied range |
| High | 500–1000 mcg | Once daily | SC injection AM fasted, 30–45 minutes before cardio. Some users split into AM + pre-workout doses at higher totals. Pre-bed dosing is generally skipped — endogenous GH pulses cover that window. |
Cycle length & outcomes
Documented cycle
8–16 weeks
Plateau after
12 wks
Cycle Structure#
AOD-9604 is a chronic-adaptation peptide, not an acute fat burner. The β3-adrenergic receptor upregulation that drives most of the effect is a slow phenotype — it needs weeks of consistent daily dosing to compound, which is why the 4-week "is this doing anything?" bail-outs almost always come up empty. Treat 8 weeks as the floor, 12 as the sweet spot, 16 as the ceiling before you rotate to something else or take a break.
"AOD9604 increased beta(3)-AR mRNA in fat from obese mice and normalized levels to that seen in lean controls, highlighting an important mechanism for the selective fat-reducing effects of this hGH fragment." — Heffernan et al., Endocrinology (2001)
No loading phase, no taper, no PCT. The compound does not touch the HPTA, does not elevate IGF-1, and does not alter glucose or lipid parameters, so there's nothing to ramp up into or step down out of.
"Chronic oral administration of AOD9604 induced a reduction in body weight and body fat, with no change in insulin, glucose, or IGF-I levels." — Heffernan et al., Am J Physiol Endocrinol Metab (2000)
Dose Ladder by Goal#
| Goal | Cycle Length | Daily Dose (SC) | Timing |
|---|---|---|---|
| First run / baseline cut adjunct | 8–12 weeks | 300 mcg | AM fasted, pre-cardio |
| Stubborn fat on a proper deficit | 12 weeks | 300–500 mcg | AM fasted |
| Stacked with GH / CJC+Ipa | 12–16 weeks | 300 mcg | AM fasted |
| GLP-1 adjunct (fat-bias on sema/tirz) | 12–16 weeks | 300 mcg | AM fasted |
| "Throw more at it" / advanced | 8–12 weeks | 500–1000 mcg split AM + pre-workout | Fasted both doses |
The dose-response flattens fast. There is no published evidence that 1000 mcg outperforms 300 mcg on body composition — users who go high are usually chasing a signal the compound doesn't provide. If 300 mcg run correctly for 12 weeks does nothing on a real deficit, more AOD is not the answer; a GH secretagogue stack or a GLP-1 is.
Onset Timing#
- Week 1–2: Nothing visible. Occasional mild appetite suppression, sometimes a slight warmth during fasted cardio. This is normal — β3-AR upregulation hasn't kicked in yet.
- Week 3–4: Fasted cardio starts to feel slightly easier to recover from; some users notice marginally better fat mobilization in stubborn depots (lower abs, lower back, flanks).
- Week 6–8: If it's working for you, this is where the scale and the mirror start to diverge from what a plain deficit alone would predict — typically 0.15–0.25 lb/week additive fat loss on top of diet.
- Week 8–12: Peak effect window. Plan your photo/show/checkpoint here.
- Week 12+: Returns taper. The weekly decay on sustained single-agent use is real; rotation or stack addition (GH, T3, GLP-1) extends the useful runway.
Bloodwork Cadence#
Minimal. This is one of the few peptides where you are not chasing labs.
- Pre-cycle: Comprehensive metabolic panel + full lipid panel + IGF-1 (baseline only, so you can confirm AOD isn't moving it — it won't).
- Mid-cycle (week 6): Optional. Skip unless stacking with HGH, insulin, or T3, in which case the other compounds drive the testing cadence.
- Post-cycle: Repeat CMP + lipids. Expect them to look like baseline.
"Across six phase I/II clinical trials, AOD9604 has not been shown to produce any significant changes in IGF-1, glucose, or lipid parameters in humans at any tested dose." — Jensen, Obesity (2006)
No HPTA recovery protocol needed. No estrogen management. No liver panels on AOD's account. If bloods shift, look at whatever else is in the stack.
Rotation & Stacking Cadence#
Running AOD continuously for 16+ weeks isn't dangerous — the safety record is the cleanest thing about this peptide — but the marginal return keeps dropping. Pragmatic rotations:
- 12 on / 4 off / 12 on for year-round recomp users running it as a background lipolytic.
- Time it with the cut block if you periodize: start AOD 2 weeks before the aggressive deficit phase, carry through the cut, drop it at maintenance.
- Stack entry point: Add AOD at the start of a CJC+Ipamorelin or low-dose HGH run rather than layering it in mid-cycle — the β3 upregulation needs the full window to compound alongside the GH-axis signal.
Results appear gradually over 6–10 weeks rather than in the first fortnight. Plan the cycle around that timeline and AOD does exactly what it's supposed to do; expect HGH-tier fat loss in 4 weeks and you'll write the same disappointed review every other impatient user writes.
Body Transformation Preview
Lean Mass Gain
0.0 lbs
0.0–0.0 lbs range
Fat Loss
2.4 lbs
1.8–3.0 lbs range
Fat Loss by Week
Risks & mistakes
Common (most users)#
- Injection-site reactions — mild redness, itch, or a small wheal at the SC site. Rotate between abdomen, flank, and thigh; use a fresh pin each shot; let reconstituted peptide come to room temp before injecting.
- Mild transient headache — usually first week only. Hydrate, add electrolytes if you're also running a deficit and cardio-heavy. Resolves without dose adjustment.
- Mild fatigue / flat feeling — infrequent, first 3–7 days. Does not persist; no action needed beyond riding it out.
- Minor GI upset (nausea, loose stool) — more common on oral tablet/troche formulations than SC. If you're running oral AOD and getting gut complaints, switch to SC — you'll also get a stronger signal for the same money.
Uncommon (dose-dependent or individual)#
- Persistent injection-site lumps or bruising — usually a technique or vial-quality issue, not the peptide itself. Check your reconstitution (swirl, don't shake; bac water, not sterile), pin size (29–31g slin), and site rotation before blaming the compound.
- Sleep disruption with pre-bed dosing — minor and inconsistent. Most users skip the pre-bed shot for this reason; morning fasted is the cleaner protocol.
- No bloodwork "drift" to watch — and this is the useful part. Across six phase I/II trials AOD did not move IGF-1, fasting glucose, lipids, or insulin sensitivity at any tested dose:
"Across six phase I/II clinical trials, AOD9604 has not been shown to produce any significant changes in IGF-1, glucose, or lipid parameters in humans at any tested dose." — Jensen MD, Obesity (2006)
A basic pre/mid/post CMP + lipid panel is enough. You do not need to chase IGF-1 on this compound.
Rare but serious#
- Hypersensitivity reaction — urticaria, facial swelling, difficulty breathing. Peptide allergy is uncommon but real; stop immediately and seek care. More often it's a reaction to a carrier, preservative, or vial contaminant than to the 16-mer itself — which is why vendor quality matters.
- Injection-site infection (abscess, cellulitis) — warmth, spreading redness, fever. This is a sterile-technique failure, not a compound effect. Stop dosing, seek antibiotics, and review your reconstitution and injection workflow before restarting.
No serious drug-attributable adverse events have been reported in the clinical record. AOD-9604 does not suppress the HPTA, does not aromatize, does not elevate IGF-1, and does not impair glucose tolerance — which is the entire design rationale of the 177-191 fragment:
"Chronic oral administration of AOD9604 induced a reduction in body weight and body fat, with no change in insulin, glucose, or IGF-I levels." — Heffernan et al., Am J Physiol Endocrinol Metab (2000)
Hard contraindications#
- Pregnancy and lactation — untested. Do not use.
- Active malignancy — untested; effects on adipose-derived signaling and tumor stroma are unknown. Do not use during active cancer treatment or surveillance.
- Known peptide hypersensitivity — prior reaction to AOD or related GH-fragment peptides is a stop.
- Competitive tested athletes — re-check current WADA and sport-specific lists before running. Growth-hormone fragments are a moving regulatory category and detection methods are evolving.
Gender and PCT considerations#
AOD-9604 is non-hormonal. It has no androgenic or estrogenic activity, does not bind the GH receptor, and does not move IGF-1. Women can run the same doses as men (250–1000 mcg/day SC) with no virilization risk. There is no HPTA suppression, no aromatization, and no PCT required — on or off, it's the same endocrine picture. Pregnancy and lactation are the only firm gender-specific lines, and only because the compound is untested in that setting, not because of a known mechanism of harm.
Stack & combine
Multipliers applied when these compounds run together. Values > 1 indicate a bonus on that axis. Tap a partner to expand the mechanism.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| synergistic | ×1.12 | ×1.22 | ×1.00 | |
| synergistic | ×1.00 | ×1.18 | ×1.05 |
FAQ — AOD-9604
Where to buy
Real Peptides
Affiliate link — we may earn a commission at no cost to you.
- AOD-9604Buy AOD-9604
Research & citations
5 studies cited on this page.
Conclusion
AOD-9604 is the cleanest play for targeted fat loss when you want the lipolytic effect of GH without the IGF-1, insulin resistance, or HPTA suppression. It shines as an adjunct in a peptide stack and is safe for both men and women.
Key takeaways:
- Standard dose: 250–500 µg SC AM fasted, 8–16 weeks; 300 µg is the research sweet spot
- Route: SubQ is the gold standard; oral bioavailability is weak
- Best protocol: AM fasted injection, 30–45 min pre-cardio, especially when stacking with CJC-1295/Ipamorelin or low-dose HGH
- Main benefit: Fat loss support via upregulated β3-adrenergic receptors, with no growth, androgenic, or glycemic side effects
- Stacks well with: GH secretagogues, GLP-1 agonists, or classic AAS/GH cutting cycles
- Side effect profile: Exceptionally mild — no IGF-1 spike, no suppression, no water retention
If you want a mild, well-tolerated fat-loss nudge on top of real diet and training (or to fine-tune a stack), AOD-9604 fills that niche. Just keep expectations realistic — it is an additive, not a magic bullet.